| |
 |
| |
|
|
| James Baker, Jr., M.D., Director |
| James Baker is an internationally recognized expert in immunology, nanotechnology, and nanomedicine. Dr. Baker invented the avidimer technology at the University of Michigan where he is the Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the Medical School . He is also the Director of M-NIMBS, which is focused on the use of nanotechnology in biomedical applications. He is one of three editors of the National Nanotechnology Initiative’s Research Directives, and Chairs the Nanotechnology for Medicine and Biology study section at National Institutes of Health (“NIH”). Dr. Baker is a board-certified internist, allergist and immunologist. |
| |
| James Matheson, Director |
| Jim Matheson is a General Partner at Flagship Ventures, an early-stage venture capital firm focused on creating, financing, and building innovative companies in the Life Science and Technology sectors. Jim joined Flagship Ventures in 2000, after previously serving for 15 years as an Officer and Fighter Pilot in the US Navy. His duties included being stationed on aircraft carriers flying combat missions in Iraq and Bosnia, as a TOPGUN Instructor, and as the Officer-in-Charge of the Navy's West Coast adversary training and evaluation squadron. Jim also gained broad experience in emerging weapons system design, testing and procurement, and was deeply involved in many of the Navy's modern IT initiatives. He continues to serve as a Commander in the US Naval Reserves. Jim earned a BS with Honors in Computer Science from the US Naval Academy and an MBA from The Harvard Business School. |
| |
| Larry Sternson, Ph.D., CEO |
| Larry Sternson is an experienced developer of drugs and pharmaceutical technology. His career which spans 35 years includes 15 years as a university professor, 10 years of big pharma experience as a senior R&D leader, and 10 years as an entrepreneur responsible for the start up and development of biotech oriented companies. He has been responsible for bringing more than 10 drug products to market based on novel drug delivery technologies. He was the founder, President and CEO of the private company, NanoSystems, whose technologies were incorporated into the first pharmaceutical products ever to use nanotechnology (2001-2004). These products are marketed by Wyeth, Merck, Par and Abbott and currently represent over $2B in annual in-market sales. NanoSystems was sold to the Elan Corporation in 1998 at which time Dr. Sternson became President of Elan’s Drug Delivery businesses, a position that he held until 2004. |
| |
|
|
|
|
